Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Methadone When Co-administered With MK-8527 in Healthy Participants
NCT07528508Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- May 2026
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mk-8527 in human immunodeficiency virus infection (HIV), sponsored by Merck & Co. Primary endpoints: Dose-Normalized Area Under the Plasma Concentration Time Curve From 0-24 Hours Postdose (AUC0-24) of R-Methadone and Dose-Normalized Area Under the Plasma Concentration Time Curve From 0-24 Hours Postdose (AUC0-24) of S-Methadone. Started May 2026; status: completed.
02
Drugs
mk-8527
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT07528508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07528508.